Newsroom

June 2017

• 
  Story Jun 20, 2017 Access to Healthcare

  Helping Syrian refugees manage chronic diseases

  Among the many Syrians uprooted by armed conflict are thousands of people with chronic conditions – such as diabetes and heart disease - whose treatment was disrupted when they fled.

• Press release Jun 20, 2017

  Novartis RTH258 (brolucizumab) demonstrates robust visual gains in nAMD patients with a majority on a 12-week injection interval

  RTH258 achieved the primary efficacy endpoint of non-inferiority to aflibercept in mean change in BCVA from baseline to week 48[1],[2] in two head-to-head pivotal Phase III studies[3],[4]…
• Press release Jun 20, 2017

  Novartis real world study shows almost half of chronic urticaria patients are not receiving any treatment despite significant disease burden

  Urgent need to improve management of chronic urticaria (CU) - a disease that causes itchy, persistent hives and swelling which last more than 6 weeks or recur over months or years - highlighted by…
• Press release Jun 19, 2017

  Sandoz receives approval in Europe for Rixathon® (biosimilar rituximab) to treat blood cancers and immunological diseases

  European Commission approves Sandoz Rixathon® to treat blood cancers and immunological diseases. Approval expected to broaden patient access to biologics and enable budget-constrained healthcare…
• Press release Jun 17, 2017

  Novartis International AG: New patient survey highlights need for more action to help severe asthma patients gain control of their disease

  Large-scale European patient survey found that 94% of severe allergic asthma patients were unable to fully control their disease  These new data underscore the disconnect between self-…
• Press release Jun 15, 2017

  FDA accepts Sandoz regulatory submission for a generic version of Advair Diskus®

  FDA accepts Sandoz ANDA for substitutable generic version of Advair Diskus® Sandoz believes its combination product will offer asthma and COPD patients same safety and efficacy as reference…
• Press release Jun 15, 2017

  Novartis' Cosentyx shows sustained improvements in signs and symptoms for both AS and PsA in up to 80% of patients at 3 years

  Cosentyx® is the first and only IL-17A inhibitor to show sustained improvements in signs and symptoms of ankylosing spondylitis (AS) and psoriatic arthritis (PsA)[1],[2]  Additional data…
• Press release Jun 08, 2017

  Novartis presents data demonstrating efficacy of AMG 334 (erenumab) in migraine prevention at the American Headache Society Annual Meeting

  Data from the comprehensive clinical program show AMG 334 (erenumab) is safe and effective at preventing migraine in patients with 4 or more migraine days per month  AMG 334 (erenumab)…
• Press release Jun 07, 2017

  Novartis interim results from global, pivotal CTL019 trial show durable complete responses in adults with r/r DLBCL

  At interim analysis, three-month overall response rate (ORR) was 45%, with 37% complete response (CR); all patients in CR at three months remained in CR at data cutoff Best ORR was 59%, with 43%…
• 
  Story Jun 06, 2017 Discovery

  Women in Science: Shilpa Shah-Mehta

• Press release Jun 06, 2017

  Novartis drug Tasigna receives EU approval for inclusion of Treatment-free Remission (TFR) data in product label

  Tasigna is the first and only tyrosine kinase inhibitor (TKI) to include information on stopping therapy in Ph+ CML-CP patients in the EU product information Approval based on Novartis trials…
• Press release Jun 05, 2017

  Novartis announces clinical collaboration with Bristol-Myers Squibb to evaluate potential treatments in metastatic colorectal cancer

  Phase I/II study to evaluate Mekinist® (trametinib) in combination with Opdivo® (nivolumab) and Opdivo + Yervoy® (ipilimumab)  Collaboration expands upon existing clinical investigation of…